Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.
Elite Pharmaceuticals Inc. (ELTP) specializes in advanced generic drug formulations with a focus on controlled-release oral medications. This news hub provides investors and industry professionals with essential updates on regulatory milestones, product developments, and strategic partnerships.
Access real-time announcements about FDA approvals, manufacturing expansions, and licensing agreements. Our curated collection includes earnings reports, clinical trial updates, and market entry strategies specific to ELTP's niche generics portfolio.
Discover how the company's DEA-registered facility and ANDA submissions position it in competitive therapeutic markets. Stay informed about innovations in pain management solutions and CNS disorder treatments through verified press releases.
Bookmark this page for streamlined access to ELTP's latest business developments. Regularly updated content ensures you never miss critical updates about this specialty pharmaceutical innovator.
Elite Pharmaceuticals (OTCQB: ELTP), a specialty pharmaceutical company focusing on niche generic products, announced they will release their fiscal year 2024 financial results on July 1, 2024. To discuss these results, Elite will host a live conference call on July 2, 2024, at 11:30 AM EDT. Shareholders are encouraged to submit their questions by June 28, 2024, for general queries, and by July 1, 2024, for financial queries. The conference call will provide an overview of financial and operating results along with a business update. The call can be accessed via specific dial-in numbers for domestic and international participants.
Elite Pharmaceuticals announced FDA approval for its generic Methotrexate Sodium 2.5 mg tablets. This approval relates to an Abbreviated New Drug Application (ANDA) and adds to Elite's portfolio of niche generic products. The generic Methotrexate, classified as an antimetabolite, will be marketed under Elite Laboratories. According to IQVIA, the generic market for Methotrexate had annual sales of $64.3 million for the twelve months ending March 2024. Elite Pharmaceuticals focuses on developing, manufacturing, and distributing immediate-release and controlled-release solid oral dose products, operating from a cGMP and DEA registered facility in Northvale, NJ.
FAQ
What is the current stock price of Elite Pharmaceuticals (ELTP)?
What is the market cap of Elite Pharmaceuticals (ELTP)?
